Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Biogen Idec (NQ: BIIB ) 226.40 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Biogen Idec < Previous 1 2 3 4 5 6 7 8 9 ... 45 46 Next > BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc. June 04, 2024 From Bernstein Liebhard LLP Via GlobeNewswire Robbins LLP Urges BIIB Investors With Large Losses to Contact the Firm for Information About the Biogen Inc. Class Action June 03, 2024 From Robbins LLP Via Business Wire Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB) June 03, 2024 From Law Offices of Howard G. Smith Via Business Wire Deep Dive Into Biogen Stock: Analyst Perspectives (17 Ratings) May 22, 2024 Via Benzinga How Is The Market Feeling About Biogen? May 20, 2024 Via Benzinga Biogen Shares Surge Following Collaboration With Delta Flight Products: What You Need To Know June 03, 2024 Biogen Inc. (NASDAQ: BIIB) shares saw a notable uptick Monday afternoon, trading higher after the company revealed a new partnership with Delta Flight Products (DFP) to enhance air travel accessibility... Via Benzinga 10 Health Care Stocks With Whale Alerts In Today's Session June 03, 2024 Via Benzinga Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel June 03, 2024 From Biogen Inc. Via GlobeNewswire BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm June 01, 2024 From Bragar Eagel & Squire Via GlobeNewswire BIIB Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Biogen Inc. Class Action May 31, 2024 From Robbins LLP Via GlobeNewswire NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc. May 31, 2024 From Kessler Topaz Meltzer & Check, LLP Via Business Wire Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder May 31, 2024 The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-approved treatment targeting the genetic cause of ALS. Via Benzinga Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors May 30, 2024 From Glancy Prongay & Murray LLP Via Business Wire Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS May 30, 2024 From Biogen Inc. Via GlobeNewswire INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors May 30, 2024 From Law Offices of Howard G. Smith Via Business Wire The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors May 30, 2024 From The Law Offices of Frank R. Cruz Via Business Wire BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! May 30, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm May 29, 2024 From Schall Law Via GlobeNewswire BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm May 28, 2024 From Bragar Eagel & Squire Via GlobeNewswire Biogen Inc. Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Against BIIB May 28, 2024 From Robbins LLP Via Business Wire BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline May 28, 2024 From Bernstein Liebhard LLP Via GlobeNewswire BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm May 24, 2024 From Bragar Eagel & Squire Via GlobeNewswire Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Biogen Inc. (BIIB) May 24, 2024 From Robbins LLP Via GlobeNewswire BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc. May 24, 2024 From Bernstein Liebhard LLP Via GlobeNewswire Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors May 23, 2024 From Kirby McInerney LLP Via Business Wire BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! May 23, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm May 23, 2024 From Schall Law Via GlobeNewswire BIIB INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit May 23, 2024 From Robbins Geller Rudman & Dowd LLP Via Business Wire Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences May 22, 2024 From Biogen Inc. Via GlobeNewswire Larimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed Drug May 21, 2024 Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data from Phase 2 study shows well-tolerated treatment with significant frataxin... Via Benzinga Exposures Product Safety < Previous 1 2 3 4 5 6 7 8 9 ... 45 46 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.